Adaptive Biotechnologies Corporation
$14.58
▲
2.63%
2026-04-21 05:05:00
www.adaptivebiotech.com
NMS: ADPT
Explore Adaptive Biotechnologies Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.23 B
Current Price
$14.58
52W High / Low
$20.76 / $6.77
Stock P/E
—
Book Value
$1.42
Dividend Yield
—
ROCE
-13.51%
ROE
-27.82%
Face Value
—
EPS
$-0.39
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
624
Beta
2.3
Debt / Equity
93.49
Current Ratio
3.34
Quick Ratio
3.23
Forward P/E
-47.37
Price / Sales
7.11
Enterprise Value
$1.96 B
EV / EBITDA
-49.86
EV / Revenue
7.07
Rating
Strong Buy
Target Price
$20.86
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Polyrizon Ltd. | $11.64 | — | $20.34 M | — | -27.56% | -25.38% | $2,235 / $2.88 | $13.05 |
| 2. | Korro Bio, Inc. | $14.28 | — | $207.54 M | — | -85.99% | -1.11% | $55.89 / $5.2 | $5.46 |
| 3. | Nuvation Bio Inc. | $5.12 | — | $1.77 B | — | -41.57% | -53.18% | $9.75 / $1.57 | $0.88 |
| 4. | Larimar Therapeutics, Inc. | $4.81 | — | $499.68 M | — | -212.84% | -1.33% | $6.42 / $1.73 | $0.94 |
| 5. | MeiraGTx Holdings plc | $10.53 | — | $857.63 M | — | -86.95% | -3.68% | $11.85 / $4.55 | $-0.07 |
| 6. | Vera Therapeutics, Inc. | $41.61 | — | $3.02 B | — | -46.31% | -50.71% | $56.05 / $18.76 | $8.48 |
| 7. | CytoMed Therapeutics Limited | $1.02 | — | $12.07 M | — | -33.09% | -50.28% | $3.68 / $0.73 | $0.43 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 71.68 M | 93.97 M | 58.88 M | 52.44 M | 47.46 M | — |
| Operating Profit | -12.77 M | 10.29 M | -25.04 M | -29.6 M | -33.84 M | — |
| Net Profit | -13.58 M | 9.55 M | -25.61 M | -29.85 M | -33.69 M | — |
| EPS in Rs | -0.09 | 0.06 | -0.17 | -0.19 | -0.22 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 276.98 M | 178.96 M | 170.28 M | 185.31 M |
| Operating Profit | -57.12 M | -155.34 M | -201.61 M | -200.19 M |
| Net Profit | -59.5 M | -159.49 M | -225.25 M | -200.19 M |
| EPS in Rs | -0.39 | -1.04 | -1.46 | -1.3 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 512.74 M | 539.38 M | 661.13 M | 856.62 M |
| Total Liabilities | 287.74 M | 336.89 M | 352.86 M | 392.52 M |
| Equity | 218.79 M | 202.71 M | 308.4 M | 464.17 M |
| Current Assets | 300.19 M | 283.75 M | 410.19 M | 562.15 M |
| Current Liabilities | 89.92 M | 98.05 M | 88.02 M | 109.79 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -45.99 M | -95.21 M | -156.32 M | -183.94 M |
| Investing CF | 37.95 M | 77.79 M | 129.65 M | 2.9 M |
| Financing CF | 30.4 M | 0.24 M | 2.25 M | 132.26 M |
| Free CF | -48.95 M | -98.88 M | -167.02 M | -200.29 M |
| Capex | -2.96 M | -3.66 M | -10.7 M | -16.35 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 54.77% | 5.1% | -8.11% | — |
| Earnings Growth % | 62.69% | 29.19% | -12.52% | — |
| Profit Margin % | -21.48% | -89.12% | -132.29% | -108.03% |
| Operating Margin % | -20.62% | -86.81% | -118.4% | -108.03% |
| Gross Margin % | 74.24% | 59.72% | 55.63% | 68.75% |
| EBITDA Margin % | -10.78% | -71.95% | -111.16% | -94.55% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.